Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lung Neoplasms × pyrotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 33 HER2-positive Breast Cancer 8 Carcinoma, Non-Small-Cell Lung 5 Brain Neoplasms 3 Advanced Breast Cancer 3 Breast Diseases 2 Stomach Neoplasms 1 Solid Tumor 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 HER2-positive Early Breast Cancer 1 HER2+ Early or Locally Advanced Breast Cancer 1 HER2 Positive Metastatic Breast Cancer 1 HER2 Positive Breast Cancer 1 HER2 Insertion Mutation Positive Advanced NSCLC 1 Estrogen Receptor-positive Breast Cancer 1 Esophageal Squamous Cell Carcinoma 1 Digestive System Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Breast Cancer Invasive 1 Breast Cancer Female 1 Advanced Digestive System Tumor 1

Interventions

Carboplatin 160 Cisplatin 98 Pemetrexed 89 Paclitaxel 89 Docetaxel 79 Gemcitabine 77 Radiotherapy 73 Erlotinib Hydrochloride 50 Bevacizumab 44 Etoposide 40 durvalumab 32 pembrolizumab 30 Magnetic Resonance Spectroscopy 25 Specimen Handling 23 Radiosurgery 23 Nivolumab 23 Gefitinib 23 Vinorelbine 21 Irinotecan 21 Topotecan 20 osimertinib 18 atezolizumab 16 Drug Therapy 16 Radiation 13 Neoadjuvant Therapy 13 Cetuximab 13 Surgical Procedures, Operative 12 Filgrastim 12 Celecoxib 12 Ipilimumab 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06563999 2024-12-10

NUMER

Sun Yat-sen University

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡